Design and statistical optimization of an eff ervescent fl oating drug delivery system of theophylline using response surface methodology
The aim of this research was to formulate eff ervescent fl oating drug delivery systems of theophylline using diff erent release retarding polymers such as ethyl cellulose, Eudragit ® L100, xanthan gum and polyethylene oxide (PEO) N12K. Sodium bicarbonate was used as a gas generating agent. Direct compression was used to formulate fl oating tablets and the tablets were evaluated for their physicochemical and dissolution characteristics. PEO based formulations produced bett er drug release properties than other formulations. Hence, it was further optimized by central composite design. Further subjects of research were the eff ect of formulation variables on fl oating lag time and the percentage of drug released at the seventh hour (D 7h ). The optimum quantities of PEO and sodium bicarbonate, which had the highest desirability close to 1.0, were chosen as the statistically optimized formulation. No interaction was found between theophylline and PEO by Fourier Transformation Infrared spectroscopy (FTIR) and Diff erential Scanning Calorimetry (DSC) studies.
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An oral controlled-release drug delivery system allows less frequent dosing and increased patient compliance (1, 2) . However, these drug delivery systems usually have a short gastric residence time, leading to poor bioavailability and incomplete drug absorption (3, 4) .
Gastroretentive drug delivery systems (GRDDS) off er an alternative approach to avoid such diffi culties and might provide a bett er therapeutic action than other drug delivery systems (5) . Prolonged gastric retention enhances bioavailability, reduces drug waste and improves the solubility of drugs that are less soluble in a high pH environment. GRDDS limit fl uctuations of plasma drug concentrations (6) (7) (8) . This feature is vital for drugs such as theophylline, which have a narrow therapeutic window.
In this study, theophylline is used as a model drug for the development of GRDDS. Theophylline is a bronchodilator used in moderate to severe reversible bronchospasms and in stable chronic obstructive pulmonary disease. It is a narrow therapeutic window drug (plasma concentration between 10-20 mg L -1 ), which requires therapeutic drug monitoring (9, 10) . Theophylline is mainly metabolized in the liver and has an elimination halflife of 6 hours (11). It has a good absorption window in the upper gastrointestinal tract, making it suitable for GRDDS. Eff ervescent fl oating tablets of theophylline have been developed in order to increase drug effi cacy, to minimize fl uctuation of drug plasma concentration and to reduce concentration-dependent adverse eff ects (12, 13) .
In this study, an eff ervescent fl oating drug delivery system of theophylline was prepared using release retarding polymers such as ethyl cellulose, Eudragit ® L100, xanthan gum and polyethylene oxide (PEO) N12K. Sodium bicarbonate was used as a gas generating agent. Ethyl cellulose and PEO N12K are hydrophobic and hydrophilic polymers, respectively (12, 13) . Eudragit ® is an anionic copolymer, whereas xanthan gum is a complex exopolysaccharide produced by Xanthomonas campestris (14, 15) . The selected polymers have good swelling properties (5) . When in contact with gastric fl uid, polymers will form a viscous matrix and retard the release of the drug from the system (16) . When in contact with gastric fl uid, sodium bicarbonate will liberate carbon dioxide gas (16, 17) . The gas entrapped within the matrix decreases the density of the tablet below 1 g cm -3 , providing buoyancy to the dosage form (16, 18) . While the system is fl oating in the gastric medium, the drug will be released slowly at a controlled rate without aff ecting the gastric emptying rate (7, 19) .
Based on previous studies, the fl oating lag time was signifi cantly controlled by the quantity of sodium bicarbonate (20) . The total polymer-to-polymer ratio and drug-to-polymer ratio signifi cantly aff ected the drug release properties and total fl oating time (21) .
The conventional optimization process allows only a single independent variable to be altered at a time, while other parameters remain constant under a specifi c set of conditions during formulation development (22) . This results in the requirement for a large number of runs to achieve target responses (18) . A statistical approach using response surface methodology (RSM) can be employed to optimize the formulation using a suitable experimental design such as central composite design (23) . RSM reduces the cost of conducting analytical studies, limits random errors and predicts accurate quantities of the polymers to achieve the target formulation (23, 24) .
The objective of the present study was to formulate an eff ervescent fl oating drug delivery system of theophylline using the gas generating agent sodium bicarbonate and release retarding polymers such as ethyl cellulose, Eudragit ® L100, xanthan gum and PEO N12K. Other objectives included optimization of the formulation of theophylline by applying a statistical approach using a central composite design and examining the eff ect of formulation variables on the dependent variables.
EXPERIMENTAL

Materials
Ethyl cellulose and PEO N12K were obtained as gift samples from Colorcon Asia Pacifi c Ltd, Singapore. Eudragit ® L 100 was obtained as a gift sample from Jebsen & Jessen Chemicals, Malaysia. Sodium bicarbonate was purchased from Ajax Finechem, Malaysia. Theophylline, xanthan gum, microcrystalline cellulose, lactose, d-mannitol min. 98 %, talc and magnesium stearate were purchased from Labchem Sdn Bhd, Malaysia.
Conventional formulation optimization
Twelve diff erent formulations with varying quantities of diff erent polymers were selected for the development of gastroretentive fl oating tablets (GRFT) of theophylline ( Table I) . The tablets were subjected to physicochemical tests and in vitro studies as described below.
Preparation of eff ervescent fl oating tablets of theophylline
All the ingredients were passed through a 500 μm sieve. Theophylline was homogenously mixed in geometrical ratio with the release retarding polymer, followed by sodium bicarbonate, diluent, talc and magnesium stearate. 1 % of talc and magnesium stearate were used in all the formulations. The fi nal blend was directly compressed into tablets with a 10-station rotary tablet punching machine (Rimek Mini Press-I) at a hardness of 3-4 kg cm -2 . Round fl at punches of 8.0 mm die size were used. Fift y tablets were produced for each formulation.
Evaluation of fl oating tablets
All fl oating tablets were evaluated for physicochemical parameters as described below.
Mass variation test. -Twenty randomly chosen tablets were weighed individually. Each tablet mass was compared with the average mass to determine if it was within the acceptance limits. 200 mg ± 7.5 % is the percentage deviation allowed for a tablet weighing 200 mg (25). mass variation (%) = 100 average mass -mass of individual tablet average mass ×
Hardness test. -The hardness of ten randomly chosen tablets was measured using a Monsanto hardness tester (T-MMT-20, Tab machines, India). The fracture load (kg cm -2 ) of ten tablets was determined individually to check tablet hardness, also represented as tensile strength. The mean values of fracture loads were used to calculate the hardness values.
Thickness test. -Twenty tablets were subjected to thickness testing using Mitutoyo vernier calipers (Model: 530-312, Japan). A thickness deviation within ± 5 % was allowed.
Friability test. -The friability test was performed using a Friabilator (Electrolab, Model: EF-2, India). Twenty pre-weighed tablets were placed in the rotating drum, which was subjected to 100 revolutions. The tablets were reweighed aft er rotations. The percentage mass loss should not be more than 1 % of total weight (26) .
Content uniformity. -Ten randomly chosen tablets were powdered in a glass mortar and 50 mg of powder was transferred into a 100 mL volumetric fl ask. The powder was dissolved in 30 mL of methanol and made up to 100 mL with 0.1 mol L -1 HCl. The solution was fi ltered and 3 mL of fi ltrate was extracted and made up to 100 mL with 0.1 mol L -1 HCl. The concentration of theophylline was determined with a validated UV spectrophotometer (LAMBDA 25, Perkin Elmer) at 270 nm.
In vitro buoyancy studies
All the formulated tablets (n = 6) were subjected to in vitro buoyancy studies. The fl oating lag time was determined in a 1 L glass beaker containing 900 mL 0.1 mol L -1 HCl. The time required for the tablet to fl oat was determined as the fl oating lag time. A fl oating lag time of less than 1 minute is desirable.
In vitro dissolution studies
In vitro release of theophylline (n = 6) was studied using an Electrolab TDT-08L dissolution tester (USP) employing a paddle stirrer. 900 mL of 0.1 mol L -1 HCl solution was maintained at 37 ± 0.5 °C at a paddle speed of 100 rpm. 5-mL aliquots were withdrawn at specifi c time intervals using a syringe fi tt ed with a 0.45 μm pre-fi lter and were immediately replaced with 5 mL of fresh dissolution medium. Each aliquot was fi ltered and diluted when necessary. The samples were analyzed using a UV spectrophotometer at 270 nm. The in vitro dissolution studies were triplicated for all batches (18) .
Formulation optimization using experimental design
A central composite design was employed using the Design-Expert (7.1.6) soft ware. The design contained two factors evaluated at two levels. The levels of two independent variables are shown below. Nine diff erent formulations were generated by the soft ware based on the conventionally optimized formulation (Table III) 
Statistical analysis and optimization
Polynomial models including linear, interaction and quadratic terms were generated for all the response variables using the Design-Expert soft ware. The best fi tt ing model was selected by comparing the coeffi cient of variation (CV), adjusted coeffi cient of determination (adjusted R 2 ), the coeffi cient of determination (R 2 ) and the predicted residual sum of squares (PRESS) provided by the soft ware. Regression coeffi cients test, F and P values were calculated by the soft ware. Analysis of variance (ANOVA) showed the eff ect of factors on the responses.
Release kinetics
The dissolution profi les of all statistically formulated batches were fi tt ed to the zero order, fi rst order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas. The order and mechanism of drug release from the matrix system were determined based on high regression (R 2 ) values (19) . response surface methodology, Acta Pharm. 66 (2016) 35-51.
The data were evaluated based on the following equations:
Zero order release kinetics:
Hixson-Crowell cube root model (erosion):
where, Q t is the amount of drug dissolved in time t, Q 0 is the initial amount of drug in the solution, M 0 is the initial concentration of drug in the dosage form, M is the remaining amount of drug in the dosage form, W 0 is the initial amount of drug in the pharmaceutical dosage form, W t is the remaining amount of drug in the pharmaceutical dosage form at time t, M t is the amount of drug released at time t, M ∞ is the amount released at time ∞ and n is the diff usion exponent. The n value is obtained as a slope by plott ing the log percentage drug released against the log time for diff erent batches (12) 
Validation of the experimental design
To validate the chosen experimental design, the experimental values of formulation responses were quantitatively compared with those of predicted values generated by the soft ware. The percentage relative error was calculated by the following equation:
Relative error (%) = 100 predicted value -observed value predicted value × In vitro buoyancy and dissolution studies of the statistically optimized formulation were performed for verifi cation of the theoretical prediction (24).
Drug-excipient interaction studies
Diff erential scanning calorimetry (DSC). -DSC analysis of the drug, polymer and the statistically optimized formulation (F0) were done using a diff erential scanning calorimeter (Mett ler Toledo DSC 823 e ). 3-10 mg of the sample was heated under nitrogen atmospheres from 0 to 280 °C at a heating rate of 10 °C/min.
Fourier transformation infrared spectroscopy (FTIR). -
The possibility of drug-polymer interaction was further investigated by FTIR using the potassium bromide pellet method. About 2-3 mg of the sample was ground with 200 mg of potassium bromide and compressed under high pressure to form a transparent disc. The disc was scanned by an IR spectrophotometer (Shimadzu, FTIR-8400S) in the region between 4000-650 cm -1 .
RESULTS AND DISCUSSION
The results of physicochemical characterization of twelve formulations developed by the conventional approach are shown in Table II same tablet mass may be due to the diff erences in the condition of the punches and in the speed of tablet compression (27) . The fl oating lag time of most of the formulations was more than 1 minute, except for B11 and B12 which took 3 seconds to fl oat (Table II) .
The target drug release is about 85-90 % at the end of 8 hours (28) . From the dissolution profi les shown in Fig. 1 , ethyl cellulose-based formulations (B1-B3) showed that only 63-64 % of the drug was released at the end of 8 hours, which was not desirable. B1, B2 and B3 had poor matrix integrity. The tablets were completely disintegrated within 4-5 hours in the dissolution medium. In B4, where the quantity of sodium bicarbonate was larger than in previous batches (B1-B3), tablets took around 3 hours to fl oat in the gastric medium and were retarded up to 8 hours. When D-mannitol was used as the diluent in B4, 90 % of the drug was released at the end of 8 hours. Hence, D-mannitol is considered as the most suitable diluent for formulating theophylline fl oating tablets.
The dissolution profi les of B1-B4 reveal clear diff erentiation of the eff ect of diluents on the drug release patt ern. The eff ect of the solubility of the diluent on the drug release pattern was explored. The water-insoluble diluent, microcrystalline cellulose (MCC), significantly retarded drug release (B1), with 60-64 % of drug being released at the end of the eighth hour. On the other hand, lactose, a water-soluble diluent, showed rapid disintegration properties; dosage forms using lactose (B2-B3) could not control drug release for more than 4 hours. However, another water soluble diluent, mannitol, showed very good retardation properties compared to lactose and MCC. Hence, further compositions used mannitol as the diluent.
Ethyl cellulose had poor buoyancy properties. The fl oating lag time of B1-B4 was still more than 1 minute, although the percentage of sodium bicarbonate had been increased to 40 % and diff erent diluents were used. On the other hand, Eudragit ® L100 based formulations (B5-B8) showed a burst release patt ern. Eudragit ® L100 was not compatible with theophylline, as the tablets completely disintegrated within 3-4 minutes in the dissolution medium. Consistent with the previous literature, Eudragit ® L100 is a good enteric coating polymer (14) . However, this polymer is not useful for theophylline fl oating drug delivery systems. As the higher density of Eudragit ® L100 may have prevented the formulation from fl oating on the gastric medium, the sodium bicarbonate concentration was increased to 10-30 % (m/m) to improve the buoyancy properties; however, this made the dosage form disintegrate rapidly. Therefore, a continuous fl oating system with prolonged release could not be achieved using Eudragit ® L100 polymer (14) . PEO N12K and xanthan gum based formulations showed good drug release patt erns and good matrix integrity. However, the xanthan gum-based formulation had poor buoyancy. Formulations based on PEO N12K were shown to be readily swellable in the gastric fl uid, thus the tablets were buoyant in less than 1 minute (12). However, formulations containing less than 50 mg xanthan gum disintegrated rapidly in the dissolution medium (12) .
Ethyl cellulose has the highest drug retarding ability compared to PEO N12K and xanthan gum, whereas Eudragit ® L100 has the least retarding ability. Drug retarding ability is aff ected by the molecular weight of the polymer (18) . Higher molecular weight polymers retarded the drug more effi ciently than polymers with lower molecular weight (12) . Based on the present results, PEO N12K appeared to be the best polymer for formulating theophylline eff ervescent fl oating tablets. Therefore, B12 was further optimized by central composite design. All nine formulations satisfi ed the criteria of the physicochemical tests (Table IV) . The fl oating lag time of S1-S9 was within 3 to 45 seconds. As the percentage of sodium bicarbonate increased, the fl oating lag time decreased. On the other hand, as the amount of PEO N12K increased, the fl oating lag time increased.
Based on the dissolution profi les, only the S7 and S9 formulations showed more than 90 % drug release by the end of 8 hours. Other formulations required more than 8 hours to achieve 100 % drug release. Drug retardation was directly proportional to the quantity of PEO N12K because of the formation of strong compactness between the particles when the concentration of polymer was higher (Table IV) . All statistical formulations fl oated in the dissolution medium for more than 8 hours and showed good matrix integrity (Fig. 2) .
Most PEO N12K based formulations followed zero order kinetics associated with the erosion mechanism (Table V) , which obeyed the rule of a controlled drug delivery system. S1, S3 and S5 formulations followed fi rst order kinetics associated with the erosion mechanism. Release mechanisms changed from fi rst order to zero order kinetics as the amount of PEO N12K exceeded 70 mg. A numerical optimization technique using a desirability approach (bilateral) and a graphical optimization method using overlay plot (Fig. 5) were employed to generate optimized formulations with the desired characteristics. The optimized formulation was selected based on a minimal fl oating lag time, release of less than 20 % of the drug in the fi rst hour, and a D 7h of 90 %. The recommended quantities of independent variables were calculated using the Design-Expert soft ware based on the plots showing the highest desirability of 1.0. The optimum values of independent variables calculated by the soft ware for the development of a GRFT of theophylline were 88.97 mg of PEO N12K and 10.46 % of sodium bicarbonate. F0 fulfi lled all the physicochemical property tests (Table VII) . In vitro buoyancy and dissolution studies of F0 were performed for verifi cation of the theoretical prediction. In vitro studies of F0 showed an ideal result. The data from the assay indicated that the statistically optimized formulation had a drug content within the USP limits, between 97.34 and 98.76 %. Percentage relative errors for fl oating lag time and D 7h were 0 and 0.54 % respectively, which were within 5 %, hence showing close agreement with the model predictions; we confi rmed the predictability and validity of F0.
Drug-excipient interactions were studied by DSC and FTIR. DSC thermograms of theophylline, PEO N12K and F0 are shown in Fig. 6 . The DSC thermogram of theophylline showed a sharp endothermic peak at 273 °C that corresponded to its melting point. The Based on the F0 thermogram, the peaks observed at 272.1, 70 and 170.9 °C corresponded to the peaks of the drug and the polymer. Slight decreases in the melting points were due to the crystallinity of the drug. The absence of any major changes in the F0 DSC thermogram indicated that there was no chemical reaction between the drug and the polymer.
The FTIR spectra of theophylline, PEO N12K and F0 are shown in Fig. 7 . Theophylline showed characteristic peaks of C=O stretching at 1716.7-1668.48, N-H stretching at 3387.11-3261.74, C=N stretching at 1568.69, C=C stretching at 1820.86 and C-N stretching at 1313.57-1284.63 cm The FTIR spectrum of F0 showed all the characteristics peaks of theophylline and PEO N12K with minor shift s, which were not signifi cant. This proved the absence of drugpolymer interactions.
CONCLUSIONS
The present study successfully indicated the capability of using the release retarding polymer PEO N12K to formulate eff ervescent tablets of theophylline that can fl oat continuously in the gastric medium and release drug in a controlled manner for 8 hours. The study has also proved that optimization using a statistical approach can reduce the number of experiments required to determine accurately the quantities of polymer and sodium bicarbonate to produce the desired tablet characteristics, avoiding unnecessary wastage of excipients and thereby reducing the cost of the fi nal product. DSC and FTIR studies showed no chemical interaction between theophylline and the polymer.
